#ESC25: Cytokinetics says heart drug data could change standard of carenews2025-08-30T07:18:35+00:00August 30th, 2025|Endpoints News|
Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drugnews2025-08-29T17:47:06+00:00August 29th, 2025|Endpoints News|
J&J’s immunology hopeful Imaavy fails Phase 2a rheumatoid arthritis studynews2025-08-29T14:00:28+00:00August 29th, 2025|Endpoints News|
BeOne plots accelerated approval for rare lymphoma drug after toplining Phase 1/2 datanews2025-08-29T10:35:34+00:00August 29th, 2025|Endpoints News|
How Scripps Research reinvented its finances to rely less on government grantsnews2025-08-28T15:43:22+00:00August 28th, 2025|Endpoints News|
Prothena reports Phase 1 Alzheimer’s data, noting high ARIA-E eventsnews2025-08-28T14:37:50+00:00August 28th, 2025|Endpoints News|
Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite lossnews2025-08-28T11:00:44+00:00August 28th, 2025|Endpoints News|
Amylyx’s old ALS drug fails in another neuro disease, focus turns to GLP-1news2025-08-27T14:47:29+00:00August 27th, 2025|Endpoints News|
BioXcel to seek label update for psych drug Igalmi after Phase 3 successnews2025-08-27T11:00:24+00:00August 27th, 2025|Endpoints News|
Antiva to tweak dosing of HPV drug, seek funding for new trial following mixed early datanews2025-08-27T11:00:12+00:00August 27th, 2025|Endpoints News|
